Results 141 to 150 of about 115,954 (269)

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri   +11 more
wiley   +1 more source

Discovery of a cryptic aminoacidic triad involved in the temperature adaptation of GH1 enzymes

open access: yesThe FEBS Journal, EarlyView.
Cold‐active enzymes retain high catalytic activity at low temperatures but are characterized by thermal instability, a behavior not fully understood. Comparison between a cold‐active GH1 and its mesophilic counterparts highlights the role of a three‐residue motif (W‐M‐F) in conferring structural stability to a mesophilic GH1.
Stefania Digiovanni   +5 more
wiley   +1 more source

SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol

open access: yes
BJU International, EarlyView.
Kevin G. Keane   +9 more
wiley   +1 more source

‘BJUI Clinical Dilemma’: Recurrent high‐grade non‐muscle‐invasive bladder cancer in 2026

open access: yes
BJU International, EarlyView.
Vignesh T. Packiam   +10 more
wiley   +1 more source

Management of Periodontal Abscesses and Endodontic‐Periodontal Lesions—A Systematic Review

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Aim To evaluate the management of periodontal abscesses and endodontic‐periodontal lesions (EPLs). Methods Seven focused questions addressed outcomes such as pocket depth (PD), bleeding on probing (BOP), tooth loss or ovoid elevation. The literature search covered three electronic databases and manual sources for intervention studies.
Henrik Dommisch   +5 more
wiley   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy